跳至主要内容
临床试验/NL-OMON53303
NL-OMON53303招募中不适用

Ketogenic diet therapy in patients with acromegaly - KetoAcro trial

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • Main study population
  • Patients (>=18 years) with active acromegaly will be recruited from the
  • Pituitary Centre Rotterdam outpatient clinic of the Erasmus MC and via the
  • *Nederlandse Hypofyse Stichting*, the national patient association. Our own
  • cohort follows over fifty patients with acromegaly on somatostatin analogue
  • monotherapy, and the National Patient Association approximately has 400 active
  • members with acromegaly, making it likely that we will be able to reach the
  • planned number of patients.
  • Sub study population
  • Patients with uncontrolled acromegaly with pegvismant treatment, will start
  • with ketogenic diet for three months, as a pilot study, with the same
  • recruitement strategy and the same in- and exclusion criteria only without
  • exclusion of pegvisomant.

排除标准

  • - Pregnancy or breastfeeding
  • - Pegvisomant treatment (not for subpopulation)
  • - Has undergone pituitary surgery or radiotherapy within 6 months prior to
  • study entry;
  • - It is anticipated that the patient will receive pituitary surgery or
  • radiotherapy during the study;
  • - History or presence of epilepsy;
  • - Participation in a trail of an experimental drug or device within 30 days
  • prior to screening;
  • - Has a mental condition rendering the subject unable to understand the nature,
  • scope and possible consequences of the study
  • - Screening HbA1c > 6,5%;
  • - Use of systemic corticosteroids within 60 days prior to screening

研究者

相似试验

Ketogenic diet therapy in patients with acromegaly | 临床试验